COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE IN COLOMBIA

被引：0
|
作者：
Lacey, M. [1 ]
Brouillette, M. [1 ]
Karpf, E. [2 ]
Lenhart, G. [1 ]
Barbeau, M. [3 ]
Russell, M. [1 ]
机构：
[1] Truven Hlth Analyt, Cambridge, MA USA
[2] Novartis Colombia, Bogota, Colombia
[3] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1218
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV72
引用
收藏
页码：A613 / A613
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction
    Zanfina, Ademi
    Alena, Pfeil Ma
    Elizabeth, Hancock
    David, Trueman
    Rola, Haroun
    Celine, Deschaseaux
    Matthias, Schwenkglenks
    SWISS MEDICAL WEEKLY, 2017, 147
  • [22] Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis
    Perera, Kanila
    Ademi, Zanfina
    Liew, Danny
    Zomer, Ella
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (09) : 966 - 972
  • [23] Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Liang, Lin
    Wu, David Bin-Chia
    Aziz, Mohamed Ismail Abdul
    Wong, Raymond
    Sim, David
    Leong, Kui Toh Gerard
    Wei, Yong Quek
    Tan, Doreen
    Ng, Kwong
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (02) : 174 - 181
  • [24] Sacubitril-Valsartan for the Treatment of Heart Failure Effectiveness and Value
    Ollendorf, Daniel A.
    Sandhu, Alexander T.
    Pearson, Steven D.
    JAMA INTERNAL MEDICINE, 2016, 176 (02) : 249 - 250
  • [25] The cost-effectiveness of sacubitril/valsartan (LCZ696) in the treatment of patients with heart failure with reduced ejection fraction in Norway
    Gundersen, V.
    Eklund, O.
    Hancock, E.
    Hussain, R.
    Ohna, A.
    EUROPEAN HEART JOURNAL, 2016, 37 : 203 - 203
  • [26] Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction
    King, Jordan B.
    Shah, Rashmee U.
    Bress, Adam P.
    Nelson, Richard E.
    Bellows, Brandon K.
    JACC-HEART FAILURE, 2016, 4 (05) : 392 - 402
  • [27] Sacubitril-valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis
    Hu, Tianyang
    Liu, Yiting
    Lou, Yake
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [28] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF ESSENTIAL HYPERTENSION IN CHINESE SETTING
    Dong, X.
    Liu, J.
    Guo, W.
    Ren, X.
    Liu, F.
    He, X.
    VALUE IN HEALTH, 2022, 25 (07) : S372 - S372
  • [29] RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Cristino, Joaquim
    Tang, Immanuel
    Ng, Caroline
    Tan, Jonathan
    Trueman, David
    Lee, Declan
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) : 1145 - 1147
  • [30] Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective
    Chin, Ken Lee
    Zomer, Ella
    Wang, Bing H.
    Liew, Danny
    HEART LUNG AND CIRCULATION, 2020, 29 (09): : 1310 - 1317
12345